Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. - Wikidata - wikimedia - TriplyDB

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

http://www.wikidata.org/entity/Q33826784

about

Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance Emerging antivirals for the treatment of hepatitis B.A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells.Quantitative detection of single base mutation by combining PNA hybridization and MALDI-TOF mass analysis.A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B.Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B.Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients.The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Molecular methods in the diagnosis and management of chronic hepatitis B.Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.Molecular diagnosis and treatment of drug-resistant hepatitis B virus.The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens.Resistance mutations of hepatitis B virus in entecavir-refractory patients.Intracellular interleukin-32γ mediates antiviral activity of cytokines against hepatitis B virus

P2860

Q27008984-3D131A38-53A9-4A54-9BDF-E4B699B4A226 Q28547647-D0EA6CAF-30F8-4BE1-B890-69DA581758FF Q33801328-FA3FD8C5-2B32-4D9C-9F6F-CFD465AEF0E9 Q33977510-92D469EC-B78B-4BFB-ABAD-F4F75137F1D4 Q34121999-62E985A3-DEA6-4DC9-A13B-4DC1C164E38B Q34638684-BBA0962A-E7CA-4472-A4ED-D436DF0CB1D1 Q34959568-4CD3D840-C69E-4A4C-802E-13008FD27D5B Q36249804-75A15CA1-5009-4237-B3F6-1467E2B31E99 Q36264766-9F34EFC4-4094-403D-BF6C-680AFBB80885 Q36385195-AC326010-30DE-4AF5-931D-BF35B0D0F95A Q36492609-09C885B7-69EE-4813-8658-6EE071F702CA Q36957080-FF01DF3B-332F-49E0-A0D9-60149758AC34 Q37097615-D87DDAB2-B67F-4977-B503-9AED46820E6F Q37124000-ABC6A0EF-9884-442B-832F-15CB19AD7697 Q37801940-C0D01624-ABCB-4F77-B6DE-BA532F2C115A Q37934571-ED1DBAF9-C277-42FD-BEB0-B3289ED9B295 Q38219020-256B802F-A95C-4776-8990-A464AA6402B3 Q40605404-36085DBA-CFB8-4DB2-AB18-66DA515F5342 Q42131024-1C34671F-A81F-447D-BEE3-12B2E949F5AE Q42221265-38F0EFFB-AFB9-44D5-B443-5E87C918F8BB Q52699085-A2D6F3F5-B4BC-4EDA-9BA5-C28BB8501461 Q58774481-B4BFFD25-1B58-4934-8C79-03853803253E

P2860

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

http://www.wikidata.org/entity/Q33826784

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Identification and characteriz ...... chronic hepatitis B patients.

@ast

Identification and characteriz ...... chronic hepatitis B patients.

@en

type

label

Identification and characteriz ...... chronic hepatitis B patients.

@ast

Identification and characteriz ...... chronic hepatitis B patients.

@en

prefLabel

Identification and characteriz ...... chronic hepatitis B patients.

@ast

Identification and characteriz ...... chronic hepatitis B patients.

@en

P1433

Q33826784-1D7B9FFE-0975-4C17-8200-B9A3DF0AAE69

P1476

Q33826784-7F012976-E2AE-4A26-A726-572E320BF7EF

P2093

Q33826784-0D495F4A-D38D-43A4-99D6-6884D78EDAAF

Q33826784-51FF4A3B-99E2-477B-A5F6-3ED6B8E52108

Q33826784-617497AA-7E6F-4F4B-B2B0-96A2AD8DC60E

Q33826784-84BB54E9-9942-4428-86A0-C6D117F319EB

Q33826784-88553F83-414B-4A43-A56E-51996A400751

Q33826784-90DC98C5-00A7-4114-929B-062628249DB1

Q33826784-9C29F2E5-4DD8-44B0-AB68-81D837FC6059

Q33826784-ABCE4702-2509-4512-825B-8C1091562460

Q33826784-E286AD75-EC06-4A66-BAEA-14D0D7EFD89C

Q33826784-E87B662B-F3BC-41C3-94C3-E4B1993F7C24

P2860

Q33826784-06487C5F-10E4-4DEC-B3A2-622444BCA808

Q33826784-0A36DC1D-6419-44D0-9FBF-E75C0ED60A4A

Q33826784-22C06A07-513B-4D93-B4AE-828936FAA73D

Q33826784-297BE3C3-F484-4B1D-80B2-77B97FB4F15A

Q33826784-2B3E8BD6-6EB5-4F87-AD79-5DFBFF754778

Q33826784-3491256E-EC77-4937-B283-070A62E00EA3

Q33826784-450062C0-D76A-468F-AA42-DA48DBA6E8A8

Q33826784-489D38B9-0095-4A69-B8AC-7AEC31571DFC

Q33826784-4E5B77FD-AE11-4454-A76B-E96BB44D1BC0

Q33826784-515863C3-5B96-4DBF-B7D4-304CD9544B71

P304

Q33826784-9763C8C6-3BC2-454D-9E00-682A11EC84C1

P31

Q33826784-1990EE78-B3B5-49F8-8ADE-F096EA3CDEAE

P356

Q33826784-7D5102D8-A451-4970-A6E4-B824B34115AB

P433

Q33826784-4535CC4E-2FB2-4F5B-9956-ECE23E6302C1

P478

Q33826784-8B8D67EE-B919-4C24-BD9B-A26E77D55EB2

P50

Q33826784-D15D8C55-F255-47D6-8BF1-9E7041533060

P577

Q33826784-7C484DAC-9AA8-4789-A57C-F4462C26D1A1

P698

Q33826784-E5646563-F723-42DD-AD46-F551F1781CD2

P932

Q33826784-4CD1BCED-09C5-46ED-B2A9-8C23E76F68E9

P356

P1433

Journal of Virology

P1476

Identification and characteriz ...... m chronic hepatitis B patients

@en

P2093

Byung Kook Kim

http://www.w3.org/2001/XMLSchema#string

Chang Hong Lee

http://www.w3.org/2001/XMLSchema#string

Eun Sook Cho

http://www.w3.org/2001/XMLSchema#string

Eun-Sook Park

http://www.w3.org/2001/XMLSchema#string

Hyo Sun Choi

http://www.w3.org/2001/XMLSchema#string

Kyun-Hwan Kim

http://www.w3.org/2001/XMLSchema#string

So Young Kwon

http://www.w3.org/2001/XMLSchema#string

Soon Young Ko

http://www.w3.org/2001/XMLSchema#string

Sung Hyun Ahn

http://www.w3.org/2001/XMLSchema#string

Won Hyeok Choe

http://www.w3.org/2001/XMLSchema#string

P2860

Telbivudine versus lamivudine in patients with chronic hepatitis B

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression.

Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

P304

4494-4503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02066-09

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20164224

http://www.w3.org/2001/XMLSchema#string

P932

2863790

http://www.w3.org/2001/XMLSchema#string